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Accumulating evidence indicates that human natural
killer (NK) cells develop in secondary lymphoid tis-
sue (SLT) through a so-called ‘‘stage 3’’ develop-
mental intermediate minimally characterized by a
CD34CD117+CD94 immunophenotype that lacks
mature NK cell function. This stage 3 population is
heterogeneous, potentially composed of functionally
distinct innate lymphoid cell (ILC) types that include
interleukin-1 receptor (IL-1R1)-positive, IL-22-pro-
ducing ILC3s. Whether human ILC3s are develop-
mentally related to NK cells is a subject of ongoing
investigation. Here, we show that antagonism of
the aryl hydrocarbon receptor (AHR) or silencing
of AHR gene expression promotes the differentiation
of tonsillar IL-22-producing IL-1R1hi human ILC3s to
CD56brightCD94+ interferon (IFN)-g-producing cyto-
lytic mature NK cells expressing eomesodermin
(EOMES) and T-Box Protein 21 (TBX21 or TBET).
Hence, we demonstrate the lineage plasticity of hu-
man ILCs by identifying AHR as a transcription factor
that prevents IL-1R1hi ILC3s from differentiating into
NK cells.
INTRODUCTION
Natural killer (NK) cells are large granular lymphocytes whose
roles in immunity include the production and release of immuno-
modulatory chemokines and cytokines as well as the direct cyto-
lytic killing of malignant or pathogen-infected cells. NK cells are
distinct from T and B lymphocytes in that NK cells do not rear-
range T cell receptor or immunoglobulin (Ig) receptor genes,
and for many years, NK cells were considered to represent the150 Cell Reports 8, 150–162, July 10, 2014 ª2014 The Authorsonly non-T/B lymphocyte population (Spits et al., 2013; Walker
et al., 2013). However, a wealth of recent data now indicates
that NK cells represent only one subset of a much larger popula-
tion of non-T/B lymphocytes now collectively described as
innate lymphoid cells (ILCs) (Spits et al., 2013; Walker et al.,
2013). ILC subsets vary in terms of their surface immunopheno-
types, transcription factor expression, and functional attributes,
and NK cells are currently classified as group 1 ILCs. Non-NK
group 1 ILCs (designated ILC1 cells) have also been described
(Bernink et al., 2013; Spits et al., 2013; Walker et al., 2013),
and whereas non-NK ILC1s can produce interferon (IFN)-g,
they are not cytolytic (Bernink et al., 2013) and do not express
the transcription factor eomesodermin (EOMES), which is selec-
tively expressed in NK cells (Gordon et al., 2012; Klose et al.,
2013; Spits et al., 2013). Given their diverse roles in immunity
and human disease, gaining an understanding of how these
various ILC populations develop is of high clinical relevance.
Within human secondary lymphoid tissue (SLT), NK cells
appear to proceed through four discrete stages of maturity as
they progress from oligopotent CD34+CD45RA+ progenitor cells
to functionally competent CD56brightCD94+ NK cells (Freud et al.,
2005, 2006). These four ‘‘lineage negative’’ (lacking CD3, CD14,
and CD19 expression) lymphoid populations may be distin-
guished by their surface expression patterns of CD34, CD117,
and CD94 such that stage 1 cells are CD34+CD117CD94,
stage 2 cells are CD34+CD117+CD94, stage 3 cells are
CD34CD117+CD94, and stage 4 cells, which bear immuno-
phenotypic and functional features that most closely resemble
peripheral blood CD56bright NK cells, are CD34CD117+/CD94+
(Freud and Caligiuri, 2006). Stage 3 cells were originally classi-
fied as ‘‘immature NK cells’’ because unlike stage 1 and stage
2 cells, they do not retain T cell or dendritic cell developmental
potential ex vivo, yet in response to in vitro interleukin-15 (IL-
15) stimulation or coculture with autologous T cells or OP9
stroma, at least a subset of stage 3 cells differentiates into stage
4 NK cells (Freud and Caligiuri, 2006). In addition, stage 3 cells
lack expression of certain receptors expressed by mature
(stage 4) NK cells, and they also lack two hallmark functions of
mature NK cells: the capacities to produce IFN-g and to perform
perforin-mediated cytotoxicity (Freud et al., 2006). Although
the role of IL-15 in driving human NK cell development (Mro´zek
et al., 1996), survival (Cooper et al., 2002), and effector function
(Carson et al., 1994) has been well documented, ex vivo culture
assays show that stage 3-to-stage 4 cell maturation in response
to IL-15 is inefficient in vitro (Freud et al., 2006; Hughes et al.,
2010). This suggests that the stage 3 population may be func-
tionally heterogeneous, and/or IL-15 on its own may be inade-
quate to drive optimal progression from stage 3 to stage 4
in vitro (Ahn et al., 2013; Freud et al., 2006; Hughes et al., 2010).
Several recent studies provide additional evidence to
suggest that the stage 3 population, minimally defined as
CD34CD117+CD94, may be comprised of a heterogeneous
group of ILC subsets, potentially including bona fide stage 3
NK cell developmental intermediates that would fit into the
aforementioned linear model of human NK cell development
as well as other non-NK lineage ILC subsets that share the
basic CD34CD117+CD94 immunophenotype. In particular,
the latter include group 3 ILCs (ILC3s), which can express
T-Box Protein 21 (TBX21 or TBET), and are defined by expres-
sion of the transcription factors RAR-related orphan receptor C
(RORC) and aryl hydrocarbon receptor (AHR) (Spits et al.,
2013). According to the most recent classification of ILC sub-
sets, ILC3s comprise at least two populations thought to be
mutually exclusive in humans: (1) a population expressing natural
cytotoxicity receptors (NCRs), including NKp44 and NKp46, as
well as IL-1 receptor (IL-1R1), IL-23R, and IL-22 (Cella et al.,
2009, 2010; Crellin et al., 2010; Hughes et al., 2010)—a popula-
tion now referred to as NCR+ ILC3 (Spits et al., 2013; Walker
et al., 2013); and (2) a lymphoid tissue-inducer (LTi) population
expressing molecules required for the development of lymphoid
tissues as well as CD117, CD127, CD161, IL-1R1, IL-23R, IL-22,
and IL-17, but not CD56 or NCRs (Spits et al., 2013;Walker et al.,
2013; and the references within). Recent fate-mapping studies
in mice suggest that the analogous NCR+ ILC3s and NK cells,
which require expression of the transcription factors TBX21
and EOMES for development (Gordon et al., 2012; Intlekofer
et al., 2005; Spits et al., 2013), represent distinct lineages
(Satoh-Takayama et al., 2010); however, adoptive transfer ex-
periments show that some NCR+ ILC3s can adopt an NK-like
phenotype in vivo (Lee et al., 2012; Qiu et al., 2012; Vonarbourg
et al., 2010), potentially representing nonconventional NK cells
or other ILC1 cells. Similar to these mouse data, clonal in vitro
assays with human cells suggest some plasticity between the
group 3 and group 1 ILC phenotypes (Cella et al., 2010; Crellin
et al., 2010; Hughes et al., 2010). Therefore, whether an ILC3
phenotype is truly a transient attribute of at least some human
NK cell precursors or whether ILC3s comprise a stable, mutually
exclusive lineage apart from NK cells in humans is still unclear.
The molecular mechanism(s) regulating these processes is also
unknown.
AHR is a ligand-activated transcription factor (Hankinson,
1995; Swanson and Bradfield, 1993) that regulates differentia-
tion of dendritic cells, regulatory T cells, TH17 cells, intraepithelial
intestinal gd T cells, and, notably, mouse NCR+ ILC3s (Kadowet al., 2011; Kremer et al., 1994; Lee et al., 2012; Platzer et al.,
2009; Quintana et al., 2008; Veldhoen et al., 2008). AHR
is required for IL-22 production by TH17 cells (Veldhoen et al.,
2008). AHR binds to halogenated aromatic hydrocarbons, and
currently described ligands include naturally occurring dietary
substances as well as synthetic substances and environmental
pollutants (reviewed by Denison and Nagy, 2003). For example,
upon exposure to light, the aromatic amino acid tryptophan can
be metabolized in vitro to products including the AHR agonist,
6-formylindolo[3,2-b]carbazole (FICZ) (Rannug et al., 1995).
Tryptophan is also metabolized to FICZ in vivo by skin keratino-
cytes upon UV light exposure (Wei et al., 1998). In contrast
to many naturally occurring AHR antagonists that have been re-
ported to act as either partial agonists or incomplete antagonists
(reviewed by Stejskalova et al., 2011), the chemical CH-223191
lacks AHR agonist activity and efficiently antagonizes activation
of AHR (Smith et al., 2011; Zhao et al., 2010).
In this study, we evaluated the impact of AHR modulation on
the differentiation and maturation of a subset of human SLT-der-
ived CD34CD117+CD94 cells with constitutive IL-22 produc-
tion and high expression of AHR and IL-1R1 ex vivo (previously
referred to as stage 3 cells and herein referred to as IL-1R1hi
ILC3s) (Freud et al., 2006; Hughes et al., 2010). Whereas
in vitro stimulation of purified IL-1R1hi ILC3s with the AHR
agonist, FICZ, acted to suppress differentiation into stage 4
mature NK cells, AHR blockade with CH-223191 or silencing of
AHR gene expression via small hairpin RNA (shRNA) induced
their differentiation into phenotypically and functionally mature
NK cells. These data suggest that AHR likely plays an important
regulatory role in the differentiation of human ILC populations
and provide evidence that its constitutive expression in IL-1R1hi
ILC3s prevents human NK cell differentiation. Furthermore,
these data indicate that inhibition of AHR activity represents a
potentially novel means by which the generation of cytotoxic,
IFN-g-producing NK cells may be achieved pharmacologically
for clinical benefit.
RESULTS
IL-1b Utilizes AHR to Maintain the IL-22+ Phenotype of
Human IL-1R1hi ILC3s
We purified fresh human stage 3 or IL-1R1hi ILC3s and
CD56brightCD94+ stage 4 NK cells from SLT to assess transcrip-
tion factor expression in each population ex vivo via real-time
RT-PCR. Although RORC and AHR were both absent, TBX21
(TBET) and EOMES were highly expressed by CD56brightCD94+
stage 4 NK cells, providing additional support for their designa-
tion as NK cells (Spits et al., 2013). In contrast, IL-1R1hi ILC3s
lacked expression of TBX21 and EOMES but constitutively
expressed RORC and AHR, the latter of which was present at
levels at least 15.50 ± 1.22-fold greater than that detected in
CD56brightCD94+ stage 4 NK cells (Figure 1A).
We therefore reasoned that IL-1R1hi ILC3s may respond to
treatment with AHR ligands. We previously showed that these
cells constitutively and selectively express abundant AHR and
IL-22 mRNA relative to earlier and later stages of human NK
cell development and that exogenous IL-1b is required to main-
tain this phenotype in the presence of the cell’s survival factor,Cell Reports 8, 150–162, July 10, 2014 ª2014 The Authors 151
Figure 1. Human IL-1R1hi ILC3s Express AHR and Respond to AHR Ligands In Vitro
(A and B) Real-time RT-PCR was used to assess (A) TBX21 (TBET), EOMES, RORC, and AHR mRNA expression ex vivo in human IL-1R1hi ILC3s
(LinCD34CD117+CD94IL-1R1hi) and stage 4 (LinCD34CD117+/CD94+) mature CD56bright NK cells, FACS purified from SLT; or (B) IL-22,CYP1A1, RORC,
EOMES, and TBX21 (TBET) mRNA expression after culture of IL-1R1hi ILC3s for 14 days in the presence of IL-15 (1 nM; salmon) or IL-15 + IL-1b (10 ng/ml; blue),
plus either carrier alone (DMSO, 1 ml/ml) or carrier containing AHR agonist (FICZ, 300 nM) or AHR antagonist (CH-223191, 3 mM). For (A) and (B), gene expression
levels were normalized to 18S mRNA, and relative quantification was performed using the DDCt method. y axis depicts fold difference in mRNA expression,
quantified relative to the condition in which expression was lowest (arbitrarily normalized to 1).
(C) Absolute number of viable cells generated from culture of IL-1R1hi ILC3s for 14 days with IL-15 plus DMSO, IL-15 plus AHR agonist FICZ, or IL-15 plus AHR
antagonist CH-223191.
Data in (A)–(C) are presented as mean ± SEM (for A and B, nR 4; for C, n = 7). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.IL-15 (Hughes et al., 2010). However, to prove that IL-1b medi-
ates its effect on IL-22 gene expression via AHR, we cultured
IL-1R1hi ILC3s for 14 days in medium containing either IL-15 or
IL-15 plus IL-1b, plus either carrier alone or an equal volume of
carrier containing an AHR agonist (FICZ) or antagonist (CH-
223191) at concentrations previously shown to modulate IL-22
production in TH17 cells (Veldhoen et al., 2009). Indeed, IL-
1b-mediated expression of IL-22 was significantly enhanced in
the presence of the AHR agonist FICZ, whereas IL-22was signif-
icantly and completely abrogated in the presence of the AHR
antagonist CH-223191, thus strongly suggesting that IL-1b me-
diates this effect via AHR (Figure 1B). As expected, culture in the152 Cell Reports 8, 150–162, July 10, 2014 ª2014 The Authorspresence of FICZ also induced expression ofCYP1A1, indicating
that AHR ligand binding and activation of downstream signaling
occurred (Wei et al., 1998). Interestingly, the addition of IL-1b
further increased the magnitude of CYP1A1 induction that
occurred in the presence of FICZ. Likewise, the combination of
FICZ and IL-1b also promoted greater retention of RORC (Fig-
ure 1B). Thus, there appears to be a synergistic interaction be-
tween AHR and IL-1b in regulating expression of these genes.
In contrast, FICZ inhibited whereas IL-1b had little effect on
expression of TBX21. Notably, blockade of AHR signaling with
CH-223191 led to an increase in TBX21 expression while inhibit-
ing expression of RORC and IL-22. Moreover, only in the
presence of CH-223191 did we detect substantial induction of
EOMES, a transcription factor that seems to be uniquely associ-
ated with the NK lineage among ILC subsets (Klose et al., 2013;
Spits et al., 2013) (Figure 1B). Thus, the presence of CH-223191
during culture of IL-1R1hi ILC3s promotes the acquisition of a
TBX21+EOMES+RORClow phenotype, similar to that observed
in freshly isolated stage 4 NK cells ex vivo.
To determine the effect of the AHR ligands on IL-1R1hi ILC3
survival, we cultured IL-1R1hi ILC3s for 14 days in the presence
of IL-15 plus either carrier (DMSO) alone or carrier containing the
AHR agonist, FICZ, or the AHR antagonist, CH-223191, at their
appropriate concentrations (Veldhoen et al., 2009). The addition
of FICZ significantly reduced the total number of viable cells,
whereas the presence of the CH-223191 slightly increased the
total number of viable cells generated in vitro (Figure 1C). Com-
parable results were obtained using an alternative AHR agonist
(curcumin) and antagonist (StemRegenin1) (T.H., unpublished
data). Thus, IL-15-mediated survival of this IL-1R1hi ILC3 popu-
lationmay itself be influenced by the expression of AHR. Further-
more, these data show that the ability of CH-223191 to abrogate
IL-1b-mediated expression of IL-22 via antagonism of AHR in
IL-1R1hi ILC3s is not the result of cell death.
AHR Prevents Differentiation of Human IL-1R1hi ILC3s
into CD56brightCD94+ Stage 4 NK Cells
We next assessed expression of NK cell maturation markers
following culture of IL-1R1hi ILC3s for 14 days with IL-15 and
either carrier alone or carrier containing FICZ or CH-223191.
Culture of IL-1R1hi ILC3s in the presence of the AHR antagonist
CH-223191 led to a significant increase in stage 4 NK cells as
determined by the relative increase in surface density of CD56
expression, as well as a significantly higher percentage of cells
expressing CD94 and having downregulated CD117 when
compared to cultures containing IL-15 and either DMSO or
IL-15 and the AHR agonist, FICZ (Figures 2A–2E). In fact, the
fraction of IL-1R1hi ILC3s expressing CD56, the mean fluores-
cence intensity of CD56, and the percentage of cells expressing
CD94 were significantly lower in the presence of IL-15 plus the
AHR agonist, FICZ, when compared to IL-1R1hi ILC3s cultured
in IL-15 plus DMSO (Figures 2A–2E). Furthermore, whereas
IL-1R1hi ILC3s cultured in IL-15 plus DMSO increased or ac-
quired expression of NKp44, NKp46, CD161, CD69, NKG2D,
and granzyme B, IL-1R1hi ILC3s cultured in IL-15 plus the AHR
agonist FICZ failed to increase expression or acquire these
molecules (Figure S1A). Thus, the AHR agonist not only appears
to counter IL-15-mediated survival of IL-1R1hi ILC3s in culture
but also suppresses IL-15-mediated differentiation of IL-1R1hi
ILC3s toward the stage 4 CD56bright NK cell phenotype.
To assess this at the single-cell level, we used fluorescence-
activated cell sorting (FACS) of IL-1R1hi ILC3s into wells seeded
with OP9-GFP stroma, which is required for survival of IL-1R1hi
ILC3s at the single-cell level (Freud et al., 2006; Hughes et al.,
2010). The OP9 stromal cell line promotes human NK cell differ-
entiation (Cupedo et al., 2009), and others have shown that it
produces mediators that antagonize the AHR pathway (Magnus-
son et al., 2013). Thus, it is possible that OP9 stroma promotes
survival and differentiation of IL-1R1hi ILC3s in part via produc-
tion of an endogenous AHR antagonist. Because of this, wecould not assess the effects of exogenous AHR antagonist on
IL-1R1hi ILC3s at the single-cell level; however, we did perform
a clonal assay comparing single IL-1R1hi ILC3s continuously
cultured in the presence of OP9 cells, IL-15, and either carrier
alone or carrier containing the AHR agonist, FICZ. The number
of wells in which clones were generated was similar for both cul-
ture conditions. As expected from our polyclonal cultures, wells
with single viable IL-1R1hi ILC3s cultured with OP9 cells in IL-15
plus FICZ were found to have CD56 expression in only 5.60% ±
0.52% of wells, versus wells with single viable IL-1R1hi ILC3s
cultured with OP9 cells in IL-15 and DMSO that had 31.29% ±
0.38% of wells with CD56 expression (Figure 2F). Similar results
were found for CD94 expression (Figure S1B), and as we previ-
ously noted (Hughes et al., 2010), compared to polyclonal cul-
tures, a higher percentage of CD94+ cells was generated during
our clonal assays that required coculture on the OP9-GFP stro-
mal cell line. These clonal data support the finding that an endog-
enous AHR antagonist is being produced by OP9-GFP stromal
cells (Magnusson et al., 2013), while also further demonstrating
that AHR and its agonist FICZ prevent differentiation of IL-1R1hi
ILC3s to stage 4 mature NK cells in vitro. Collectively, our poly-
clonal and single-cell data suggest that activation of constitu-
tively expressed AHR with an AHR agonist suppresses IL-15-
mediated differentiation of IL-1R1hi ILC3s toward the stage 4
CD56bright NK cell phenotype.
It should be noted that there was no significant surface
expression of the Fc receptor, CD16, or killer cell Ig-like
receptors (KIRs), among stage 4 mature CD56bright NK cells
derived in vitro from IL-1R1hi ILC3s in the presence of the AHR
antagonist, suggesting that inhibition of AHR cannot drive
stage 4 CD56bright NK cells to stage 5 CD56dimCD16+KIR+/
NK cells in vitro (Figure S1A) (Freud and Caligiuri, 2006; Freud
et al., 2006). Indeed, stage 4 mature CD56bright NK cells isolated
directly from SLT lacked detectable expression of AHR (Hughes
et al., 2010; Figure 1A).
AHR Prevents the Differentiation of Human IL-1R1hi
ILC3s into Functional NK Cells that Produce IFN-g
Freshly isolated IL-1R1hi ILC3s cannot produce IFN-g ex vivo
(Freud et al., 2006; Hughes et al., 2010). Given the upregulation
of TBX21 and EOMESmRNA (Figure 1B), as well as the acquisi-
tion of the stage 4 CD56bright NK cell immunophenotype by
IL-1R1hi ILC3s that occurred in response to AHR antagonism
(Figure 2), we next investigated whether antagonism of AHR
might promote differentiation to a functional NK cell as well. To
this end, IL-1R1hi ILC3s freshly isolated from SLT were placed
into culture for 14 days with IL-15 plus either carrier alone or car-
rier containing the AHR agonist or antagonist. On day 14, cells
were counted, and an equal number of progeny generated in
each culture condition were used for effector function assays
detailed below.
To assess the capacity for monokine-induced IFN-g produc-
tion, an equal number of cells were incubated for 12 hr in either
media alone (‘‘unstimulated’’) or media containing IL-12, IL-15,
and IL-18. Surface expression of NKmaturationmarkers was as-
sessed in conjunction with intracellular (IC) flow cytometric stain-
ing for IFN-g protein (Figures 3A–3C). Cell-free supernatants
were also assessed for IFN-g secretion by ELISA (Figure 3D).Cell Reports 8, 150–162, July 10, 2014 ª2014 The Authors 153
Figure 2. AHR Prevents Differentiation of Human IL-1R1hi ILC3s to NK Cells In Vitro
(A–E) IL-1R1hi ILC3s were FACS purified from SLT, cultured for 14 days under indicated conditions, then assessed for expression of CD56, CD94, and CD117.
Data in (A) and (D) depict staining in a representative donor (CH-223191, dark gray; DMSO, light gray; FICZ, dashed line; nR 8). Data in (B), (C), and (E) depict
average: (B) mean fluorescence intensity (MFI) of CD56 surface expression (n = 12); (C) percentage of cells that acquired CD94 surface expression (n = 8); and (E)
percentage of cells that lost CD117 and acquired CD94 (n = 4). Data are presented as mean ± SEM. *p < 0.05; **p < 0.005.
(F) Single IL-1R1hi ILC3s were cultured on OP9-GFP+ stroma with IL-15 plus either DMSO carrier or AHR agonist FICZ. After 14 days, each of 60 replicate wells
was individually assessed for CD56 surface expression via flow cytometry as previously described (Hughes et al., 2010). Of the wells, 100% scored positive for at
least some CD56 expression. Data represent mean ± SEM (**p < 0.005; n = 2 donors).Monokine stimulation induced only modest levels of IFN-g
expression by IL-1R1hi ILC3s cultured in the presence of IL-15
with carrier or IL-15 plus FICZ. In contrast, among the progeny
of IL-1R1hi ILC3s generated during culture in IL-15 with the
AHR antagonist CH-223191, monokine stimulation induced154 Cell Reports 8, 150–162, July 10, 2014 ª2014 The AuthorsIFN-g expression in a significantly greater percentage of cells
(Figures 3A and 3B) and also significantly increased IFN-g pro-
duction among the CD94+ fraction derived in vitro (Figure 3C).
ELISAs indicated that supernatants from IL-1R1hi ILC3s cultured
in vitro with IL-15 plus carrier or IL-15 plus AHR agonist
Figure 3. AHR Prevents IL-1R1hi ILC3s from
Acquiring the Capacity for IFN-g Production
In Vitro
(A–D) IL-1R1hi ILC3s were FACS sorted from SLT
and cultured in conditions shown. After 14 days,
an equal number of cells from each condition were
stimulated for 12 hr with IL-12, IL-15, and IL-18
then assessed for (A)–(C) IC (n = 3) or (D) secreted
(n = 4) IFN-g production. (A) represents an indi-
vidual donor (CH-223191, dark gray; DMSO, light
gray; FICZ, dashed line), whereas (B)–(D) depict
the average result frommultiple donors, presented
as mean ± SEM. *p < 0.05.contained scant amounts of IFN-g (4.32 ± 1.39 ng/ml or%0.3 ±
0.08 ng/ml, respectively) following monokine stimulation;
however, IL-1R1hi ILC3s cultured with IL-15 and AHR antagonist
secreted significantly greater IFN-g, averaging 19.9 ± 4.75 ng/ml
when activated with IL-12, IL-15, and IL-18 (Figure 3D). Although
IL-1R1hi ILC3s cultured in vitro with IL-15 and carrier alone also
produced some IFN-g, the addition of AHR antagonist resulted in
cells producing IFN-g at levels similar to those seen in freshly iso-
lated stage 4 CD56bright NK cells (Freud et al., 2006). Thus, acti-
vation of constitutively expressed AHR in human IL-1R1hi ILC3s
prevents their differentiation into functional group 1 ILCs or NK
cells that produce IFN-g.
AHR Prevents the Differentiation of Human IL-1R1hi
ILC3s to Cytolytic NK Cells
Human IL-1R1hi ILC3s also lack perforin and natural cytotoxicity
against NK-sensitive K562 target cells ex vivo (Freud et al., 2006;
Hughes et al., 2010). We investigated whether AHR signaling in-
fluences acquisition of cytolytic effector functions following cul-
ture of IL-1R1hi ILC3s in vitro. Culture in the presence of the AHR
antagonist CH-223191 promoted in vitro acquisition of tumor ne-
crosis factor-related apoptosis-inducing ligand (TRAIL), a sur-
face receptor used by NK cells to induce apoptosis of target cells
expressing appropriate cognate death receptors (Kashii et al.,
1999). TRAIL expression was especially pronounced within the
subset of IL-1R1hi ILC3s that had also acquired CD94 during cul-
ture in IL-15 plus CH-223191 (Figure 4A). Although there were
twice as many CD117CD94+ cells resulting from IL-1R1hi
ILC3s cultured with IL-15 plus the AHR antagonist CH-223191
(Figure 2E), perforin expression was only moderately increased
in this population when compared to the CD94+ cells resulting
from culture of IL-1R1hi ILC3s with IL-15 plus carrier alone (Fig-
ure 4B). A standard 51Cr release cytotoxicity assay was per-
formed using IL-1R1hi ILC3s cultured for 14 days with IL-15
plus carrier, IL-15 plus FICZ, or IL-15 plus CH-223191. CellsCell Reports 8, 150–generated in the latter condition showed
significantly and substantially greater
lysis of K562 target cells compared to
the two former conditions (Figure 4C).
Although IL-1R1hi ILC3s cultured in vitro
with IL-15 and carrier were capable of
low levels of target cell lysis, the addition
of AHR antagonist boosted cytolytic ac-tivity significantly, resulting in killing at levels comparable to
that of freshly isolated stage 4NK cells (Freud et al., 2006). As ex-
pected, this cytolytic effect was even more pronounced in the
CD94+ fraction (Figure 4D). Thus, AHR inhibits IL-1R1hi ILC3s
from acquiring cytolytic effector cell function typically found in
stage 4 CD56bright NK cells.
AHR mRNA Knockdown Promotes In Vitro
Differentiation of IL-1R1hi ILC3s
To confirm the results derived from pharmacologic antagonism
of AHR by genetic targeting, we used a lentiviral vector (PSIH1)
expressing GFP either without (PSIH1-H1-copGFP, ‘‘empty vec-
tor’’) or with (PSIH1-H1-copGFP-AHR, ‘‘AHR shRNA’’) a shRNA
directed against AHR using a previously described sequence of
Boitano et al. (2010). We first validated the vector’s ability to
knock down AHRmRNA in the NKL human NK cell line because
the low number of primary IL-1R1hi ILC3s we were able to obtain
and infect with lentiviral vector precluded validation in this
population. As depicted in Figure 5A, NKL cells expressed com-
parable levels of AHR prior to and following infection with empty
lentiviral vector (AHR expression after infection with empty
vector was 114.48% ± 12.42% of uninfected); however, when
NKL cells were infected with lentiviral vector containing AHR
shRNA, AHR transcript was diminished by 59.5% compared to
expression seen following infection with empty vector.
We next used each lentiviral vector to infect FACS-sorted
IL-1R1hi ILC3s from the same donor’s SLT and cultured these
two populations in identical conditions with IL-15 plus carrier
(DMSO) alone for 14 days in vitro. Compared to IL-1R1hi ILC3s
infected with empty vector, infection with lentivirus containing
AHR shRNA increased the percentage of cells expressing
CD94, TRAIL, and CD56 and decreased the percentage of cells
expressing CD117 (Figures 5B and 5C). These data are consis-
tent with results obtained using the AHR antagonist CH-
223191. Likewise, relative to IL-1R1hi ILC3s infected with empty162, July 10, 2014 ª2014 The Authors 155
Figure 4. AHR Prevents IL-1R1hi ILC3s from Acquiring Cytotoxic Effector Function In Vitro
(A–D) IL-1R1hi ILC3s were FACS sorted from SLT and cultured under the indicated conditions.
(A and B) On day 14, flow cytometry was used to assess (A) TRAIL and CD94 surface expression, or (B) IC perforin and CD94 surface expression. Histograms
depict staining in a representative donor after gating on CD94+ lymphocytes (CH-223191, dark gray; DMSO, light gray; FICZ, dashed line). For (A) and (B), nR 3.
(C and D) Cytotoxic activity was assessed against the K562 target cell line using an equal number of (C) total progeny or (D) FACS-sorted CD94+ and CD94 cells
generated from IL-1R1hi ILC3s after 14 days in conditions indicated. Cells were plated in triplicate, and target cell lysis was assessed at (C) each effector:target
(E:T) ratio indicated (n = 3) or (D) an E:T ratio of 5:1 (CD94+, black; CD94, gray; n = 4). Data in (C) and (D) are presented as mean ± SEM. ***p < 0.005; **p < 0.01;
*p < 0.05.vector, infection of cells with lentivirus containing AHR shRNA
increased the percentage of cells that were positive for IC
IFN-g following monokine stimulation (Figure 5D). This effect
was especially pronounced among GFP+ cells that had also
acquired CD94 during culture (Figures 5E and 5F). Too few in-
fected cells and high background staining precluded us from
validating the acquisition of cytolytic function via 51Cr-release
assay or staining for CD107a, respectively. Nonetheless, these
data confirm our observations regarding the functional acquisi-
tion of IFN-g production by IL-1R1hi ILC3s cultured in vitro in
the presence of the AHR antagonist CH-223191 and support
the notion that the AHR transcription factor prevents the pheno-
typic and functional differentiation of human IL-1R1hi ILC3s to
stage 4 mature CD56bright NK cells.
DISCUSSION
The recent discovery and characterization of an ILC3 popula-
tion with immunophenotypic features overlapping those of
CD34CD117+CD94 stage 3 human NK cell developmental in-
termediate (Cupedo et al., 2009; Freud et al., 2006; Hughes et al.,
2009, 2010; Spits et al., 2013; Walker et al., 2013) have chal-
lenged us to further examine our original four-stage model of hu-
man NK cell development (Freud et al., 2006). Indeed, because
stage 3 immature NK cells or IL-1R1hi ILC3s neither produce
IFN-g nor display cytolytic activity ex vivo yet in bulk or single-
cell culture can give rise to functionally and phenotypically156 Cell Reports 8, 150–162, July 10, 2014 ª2014 The Authorsmature NK cells, Freud et al. originally characterized this
population as committed immature NK cells (Freud et al.,
2006). However, it is now known that a major fraction of the
CD34CD117+CD94 (stage 3) population constitutively ex-
presses RORC, AHR, and IL-22, the latter of which is also
secreted in response to cytokine stimulation (Cella et al., 2009,
2010; Hughes et al., 2010). In light of this, as well as fate-map-
ping studies in mice and some in vitro studies in humans, this
IL-22-producing population is often considered to comprise a
distinct lymphocyte lineage, separate from NK cells (Crellin
et al., 2010; Satoh-Takayama et al., 2010). Nonetheless, some
studies indicate plasticity between group 1 and group 3 ILC
phenotypes (Ahn et al., 2013; Cella et al., 2010; Lee et al.,
2012; Qiu et al., 2012; Vonarbourg et al., 2010), so whether
IL-22-producing IL-1R1hi ILC3s comprise a stable ILC lineage
distinct from NK cells or whether at least a fraction can serve
as physiologic stage 3 NK cell precursors is a subject of ongoing
debate and investigation. Furthermore, the transcriptional
machinery responsible for such plasticity or lack thereof has
not been explored in humans.
In the current report, we provide compelling evidence that a
single transcription factor, AHR, prevents IL-22-producing IL-
1R1hi ILC3s from differentiating into CD56bright NK cells in the
presence of IL-15. First, we show that the IL-1R1hi ILC3 pheno-
type and expression of IL-22 in this population are dependent
upon expression of AHR, which in turn is maintained by IL-1b.
We next demonstrate that in the presence of IL-15, human
IL-1R1hi ILC3s respond to antagonism of AHR—whether due to
the pharmacologic AHR antagonism or via direct genetic target-
ing of the transcription factor—with quantitatively and qualita-
tively enhanced differentiation into stage 4 CD56bright NK cells
in vitro. Specifically, inhibition of AHR resulted in diminished
CD117 surface expression, increased CD94, CD56, and TRAIL
expression along with a moderate increase in perforin expres-
sion, as well as enhanced functional maturation as evidenced
by the acquisition of both IFN-g production and cytotoxicity
against tumor cell targets. AHR antagonism also inhibited
RORC expression and promoted expression of the transcription
factors TBX21 (TBET) and EOMES. Notably, the expression of
EOMES—recently shown to maintain maturation of murine NK
cells (Gordon et al., 2012) and uniquely associate with NK cells
rather than non-NK ILC1s (Klose et al., 2013; Spits et al.,
2013)—was induced at high levels only in the presence of the
AHR antagonist. Collectively, these data support the conclusion
that AHR inhibits the differentiation of human IL-1R1hi ILC3s into
functionally mature human NK cells in the presence of IL-15
in vitro.
Importantly, the data presented here are in agreement with
recent findings in mice and humans that attest to the presence
of lineage plasticity among ILC subsets (Bernink et al., 2013;
Cella et al., 2010; Vonarbourg et al., 2010). For example, Vonar-
bourg et al. demonstrated that in the presence of IL-12, murine
NCR+ ILC3s could downregulate expression of RORgt and
adopt an NK cell-like phenotype (Vonarbourg et al., 2010). Cella
et al. showed that culture in IL-2 could promote differentiation of
human NCR+ ILC3s toward an IFN-g-producing phenotype at
the expense of an IL-22-producing phenotype in vitro (Cella
et al., 2010). Likewise, Bernink et al. recently reported that hu-
man NCR+ ILC3s could serve as precursors to IFN-g-producing
non-NK ILC1s (Bernink et al., 2013). The data we present here
provide additional evidence for potential lineage plasticity
among human ILC subsets and support the notion that AHR pre-
vents human IL-1R1hi ILC3s from giving rise to EOMES+, CD94+,
IFN-g-producing, cytolytic stage 4 CD56bright NK cells.
Interestingly, in light of fate-mapping studies in mouse models
(Kiss et al., 2011; Satoh-Takayama et al., 2010; Vonarbourg
et al., 2010), these human data call into question what defines
anNK cell. Should NK cells be defined by their molecular, pheno-
typic, and functional attributes regardless of their derivation, or
must they never have traversed a RORgt+ intermediate pheno-
type? The data presented here raise the possibility that at least
human NK cells may be derived via two distinct pathways: one
that bypasses and one that could potentially progress through
an IL-1R1hi ILC3 intermediate stage. Whether this pathway
(i.e., IL-1R1hi ILC3/ CD56bright NK via AHR blockade) occurs
naturally in vivo in humans is still unclear and is a subject of
ongoing investigation.
In light of our human data presented herein, it is notable that
Shin et al. recently reported that NK cells derived from AHR/
mice actually have diminished IFN-g production and cytotox-
icity, so these mice are more prone to developing tumors (Shin
et al., 2013). In addition to the inherent species differences and
the distinct differences in human and mouse NK cell develop-
mental microenvironments that are now well established (Yu
et al., 2013), it is known that AHR controls CD117 expressionas demonstrated in gd T cells (Kadow et al., 2011), in mouse
RORgt+ cells (Kiss et al., 2011), and in human ILC3s (this report).
It is also well known that mice lacking CD117 (c-Kit) or its ligand
(KL) have poor NK cell development (Colucci and Di Santo, 2000;
Shibuya et al., 1995). Thus, it is conceivable if not likely that the
genetic disruption of AHR in mice leads to low or absent CD117,
which in turn leads to poor NK cell development, possibly
through the elimination of a critical ILC3-like NK cell precursor.
When taken in the context of other recently published reports
regarding ILC development and plasticity (Bernink et al., 2013;
Cella et al., 2009; Crellin et al., 2010; Spits et al., 2013; Vonar-
bourg et al., 2010), our study further suggests that ILCs may
bemodified by cues from themicroenvironment, the clinical rele-
vance of which is not yet clear. Indeed, ILC populations have
been shown to regulate and are implicated in a host of patholog-
ical processes (Powell et al., 2012; Sonnenberg et al., 2012; Spits
and Di Santo, 2011). Moreover, it is known that AHR-mediated
gene regulation is highly context dependent and cell-type spe-
cific (Frericks et al., 2007). Notably, AHR has been shown to
regulate gene transcription in many cell types, including those
of the immune system (Kadow et al., 2011; Kiss et al., 2011; Plat-
zer et al., 2009; Veldhoen et al., 2008), which possess AHR-
responsive elements in their promoters (Sun et al., 2004). In
particular, AHR has been shown to regulate the development
of the IL-22-producing TH17 lineage of T cells (Veldhoen et al.,
2008), and at least some of AHR’s functions have been reported
to be ligand binding specific (Burbach et al., 1992). Importantly,
the addition of AHR agonists, which trigger activity of AHR as a
transcription factor (Wei et al., 1998), to culture medium has
been shown to enhance TH17 differentiation and IL-22 produc-
tion (Quintana et al., 2008). Our data, which indicate that adding
an AHR agonist to IL-1R1hi ILC3 cultures in the presence of IL-1b
results in a substantial increase in IL-22 production, would sup-
port this earlier report in T cells.
AHR is also involved in metabolizing xenobiotics and drugs
(Denison and Nagy, 2003) and has reported involvement in carci-
nogenesis, metabolically activating environmental pollutants
to create carcinogens, such as benzo[a]pyrene (Shimizu et al.,
2000). Epidemiological studies have shown that certain genetic
polymorphisms—specifically polymorphisms that result in a
higher level of AHR activity—are associated with an increased
risk of developing certain types of cancers, and AHR is constitu-
tively active in rapidly growing tumors and immortalized tumor
cell lines (DiNatale et al., 2011). Recently, an endogenous tu-
mor-promoting AHR agonist was discovered in the setting of gli-
oma (Opitz et al., 2011), raising the possibility that endogenous
AHR agonists could play a similar role in other types of can-
cer—promoting tumor cell survival, while impeding NK develop-
ment thereby limiting tumor cell lysis. Indeed, we have previously
shown that higher expression of IL-1b, which we showmaintains
AHR expression and the IL-22+ phenotype in IL-1R1hi ILC3s
(Hughes et al., 2010; this report), is associated with an unfavor-
able prognosis in a subset of cytogenetically normal patients
with acute myeloid leukemia (Marcucci et al., 2008).
It has been long known that cues from the local microenviron-
ment regulate NK cell development and acquisition of effector
functions (Yu et al., 2013). It has also been previously reported
that treatment with AHR antagonists in vitro may lowerCell Reports 8, 150–162, July 10, 2014 ª2014 The Authors 157
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progrowth and antiapoptotic signals in several head and neck
cancer cell lines (DiNatale et al., 2011). If this finding also holds
true in vivo, dampening of AHR signaling may represent a useful
strategy to combat certain cancers. Importantly, we observed
that AHR antagonism seemed to be required for IL-1R1hi ILC3
induction of EOMES expression and resulted in enhanced killing
of tumor target cells—a finding that is in agreement with those of
Gill et al., who used amousemodel to show that high levels of NK
cell EOMES expression were associated with decreased tumor
burden and increased rate of survival (Gill et al., 2012). Our
data from this report would support the notion that pharmaco-
logic inhibition of AHR signaling could promote differentiation
of IL-1R1hi ILC3s to cytotoxic, IFN-g-producing stage 4 mature
NK cells, thus bolstering NK cell effector function, while simulta-
neously differentiating the tumor cell and increasing its suscep-
tibility to apoptosis and/or inhibiting its survival, thus potentially
reducing tumor burden via two different, but complementary,
mechanisms. Because at least some of AHR’s functions are
reported to be ligand binding specific (Veldhoen et al., 2009),
some have proposed the use of AHR as a unique ‘‘druggable’’
target for therapeutic immunomodulation (Murray et al., 2010).
We and others have previously demonstrated that exposure
of human IL-1R1hi ILC3s to IL-15 and IL-1b expands this subset
of IL-22-producing cells while maintaining expression of AHR
(Cella et al., 2010; Hughes et al., 2010). Here, we show that an
AHR agonist prevents the upregulation of NCRs, granzyme B,
and NK cell function in the presence of IL-15 and profoundly in-
creases the cell’s expression of IL-22 via activation of AHR, and
the addition of IL-1b accentuates this effect. It is thus possible
that IL-1b and AHR work together to tightly repress IL-1R1hi
ILC3 differentiation to stage 4 mature NK cells; that is to say
that IL-1b induces AHR and thus helps expand IL-22-producing
IL-1R1hi ILC3s in response to appropriate environmental stimuli
when these cells are necessary for mucosal immunity. If IL-22-
producing IL-1R1hi ILC3s are not desirable or necessary in
certain inflammatory conditions, antagonism/blockade/downre-
gulation of IL-1R1 and/or AHR could potentially prevent autoim-
munity and consequent tissue damage by efficiently converting
many IL-1R1hi ILC3s with TH17-like properties to stage 4 mature
NK cells endowed with TH1-like properties and effector func-
tions. Thus, IL-1b-mediated maintenance of AHR expression
might not only serve to promote IL-22 production but may also
inadvertently allow easy access to a ‘‘kill switch’’ allowing these
cells to differentiate to stage 4 NK cells upon exposure to an AHR
antagonist and a second set of stimuli to quickly differentiateFigure 5. AHR Knockdown via shRNA Confirms that AHR Prevents the
(A)AHRmRNAwas quantified via real-time RT-PCR in the humanNKL cell line prio
H1-copGFP, ‘‘Empty vector’’; middle) or a lentiviral vector containingAHR shRNA
AHR mRNA expression in uninfected NKL cells, arbitrarily set at 100%. Mean ±
(B) Histograms depict IL-1R1hi ILC3s from representative donor infected with em
then stained for expression of CD94, TRAIL, CD56, and CD117 on the surface o
(C) Contour plots depict coexpression of CD94 andCD117 on the surface of GFP+
containing AHR shRNA after 14 days of culture.
(D–F) IL-1R1hi ILC3s were infected with empty vector or vector containing AHR sh
and stained for IC IFN-g protein expression.
(D) Histograms depict IC IFN-g protein expression in unstimulated (white) or mon
(E and F) Monokine-induced IFN-g within GFP+ infected cells coexpressing CD9
donors. Values in (F) are calculated as described for Figures 3B and 3C and depthis population of IL-1R1hi ILC3s. Together, these data establish
AHR as a transcription factor whose constitutive expression in
IL-1R1hi ILC3s prevents their differentiation into NK cells.
EXPERIMENTAL PROCEDURES
Isolation of Human NK Precursors from SLT
All protocols were approved by The Ohio State University institutional review
board. Fresh, normal human tonsils were obtained, and NK developmental in-
termediates, including IL-1R1hi ILC3s, were isolated as described (Freud et al.,
2006; Hughes et al., 2010). All populations were sorted toR95% purity with a
FACSAria II cell sorter (BD Biosciences).
Flow Cytometry
All antibodies used for flow cytometry were purchased from BD Biosciences,
except CD56 (Beckman Coulter) and CD94 (R&D Systems). IC staining for per-
forin and IFN-g was performed after surface staining. Cells were analyzed
immediately as previously described (Freud et al., 2005) using an LSR II cytom-
eter (BD Biosciences) and FlowJo software (TreeStar). Nonspecific staining
was detected with an appropriately labeled isotype antibody.
Real-Time RT-PCR
mRNA was obtained by lysing a portion of each FACS-sorted population in
approximately equal quantity (R1 3 104 cells). RNA was isolated using the
RNeasy Micro Kit (QIAGEN), and cDNA was synthesized according to the
manufacturer’s instructions using the M-MLV Reverse Transcriptase kit (Invi-
trogen). Real-time RT-PCR was performed on an ABI Prism 7900HT (Applied
Biosystems). TaqMan primer/probe sets for AHR, CYP1A1, and IL-22 were
purchased from Applied Biosystems. Detection of TBX21 and EOMES was
performed using primers with sequences as previously described (Yu et al.,
2006). Gene expression was normalized to 18S mRNA internal control, then
analyzed by the DDCt method (Fehniger et al., 1999).
Cell Culture
FACS-purified IL-1R1hi ILC3s were cultured in a round-bottom 96-well plate
(CoStar) at a starting density of 25,000 cells/ml in a-modified Eagle’s medium
(MEM) containing 10% fetal bovine serum (FBS), penicillin G (100 mg/ml), and
streptomycin (100 mg/ml) (Invitrogen), supplemented with recombinant human
IL-15 (1 nM; Amgen) with or without IL-1b (10 ng/ml; PeproTech), and either
carrier alone (DMSO, 1 ml/ml; Invitrogen) or carrier containing AHR agonist
(FICZ, 300 nM; Enzo Life Sciences) or AHR antagonist (CH-223191, 3 mM; Cal-
biochem) at concentrations previously reported to modulate TH17 differentia-
tion (Veldhoen et al., 2009). Half the medium was removed every 2–3 days and
replaced with medium containing 23 cytokines. After 14 days of culture, cells
were counted for viability with trypan blue prior to assays.
Single-Cell Culture
A FACSAria II was used to deposit single IL-1R1hi ILC3s directly into each well
of a 96-well flat-bottom plate containing GFP+ murine OP9 stromal cells in
a-MEM containing 10% FBS and IL-15 plus either DMSO carrier or AHR
agonist, FICZ. Half the medium was removed every 2–3 days and replacedDifferentiation of IL-1R1hi ILC3s to Stage 4 Mature NK Cells
r to infection (left) and following infection with an empty lentiviral vector (PSIH1-
(PSIH1-H1-copGFP-shAHR, ‘‘AHR shRNA’’; right). Values shown are relative to
SEM is shown (n = 4). **p < 0.01.
pty vector (white) or vector containing AHR shRNA (gray), cultured for 14 days,
f GFP+ cells.
IL-1R1hi ILC3s from a representative donor infectedwith empty vector or vector
RNA, cultured for 14 days, then stimulated for 12 hr with IL-12, IL-15, and IL-18,
okine-stimulated (gray) GFP+ infected cells from a representative donor.
4 shown in (E) as a representative donor and in (F) as a mean result of multiple
icted as mean ± SEM. For (B)–(F), nR 3. *p < 0.05.
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with fresh medium containing 23 cytokines. After 14 days, each of 60 replicate
wells was individually assessed via flow cytometry for human CD56 surface
expression as previously described (Hughes et al., 2010). Wells were scored
as positive when the proportion of GFP lymphocytes expressing CD56 ex-
ceeded 2% (corresponding to level of background staining with isotype con-
trol monoclonal antibody).
Effector Function Assays
FACS-sorted IL-1R1hi ILC3swere cultured as indicated for 14 days. Progeny of
these cells were assessed either in bulk or after FACS sorting CD94+ and
CD94 subsets generated during culture. Cells were counted, and an equal
number of cells generated in each culture condition were used for each assay.
Cytotoxicity assay against K562 targets was performed as described (Trotta
et al., 1998).
IFN-g production was measured as previously described, either via ELISA
(Trotta et al., 2005), or via IC flow cytometric staining (Cooper et al., 2001).
Results following 12 hr stimulation with IL-12 plus IL-15 plus IL-18 were
compared to parallel controls incubated in the absence of monokines. Percent
IFN-g+ (‘‘% IFN-g+’’) was calculated by subtracting percentage of cells pro-
ducing IFN-g in the absence of stimulation (value was <1%) from those pro-
ducing IFN-g in response to monokine stimulation.
Lentiviral Infection of Primary Human IL-1R1hi ILC3s
The lentiviral expression vector PSIH1-H1-copGFPwas obtained from System
Biosciences. To generate PSIH1-H1-copGFP-shAHR, hairpin oligos directed
against AHR sequences described previously by Boitano et al. (2010) were
phosphorylated, annealed, and ligated into predigested PSIH1-H1-copGFP
vector. 293T cells were grown to 80% confluence, then transfected as previ-
ously described (Trotta et al., 2012). Infectious supernatant from PSIH1-H1-
copGFP or PSIH1-H1-copGFP-shAHR retroviral transfection of the 293T cell
line was collected after 48 hr. IL-1R1hi ILC3s were FACS sorted from SLT
and immediately subjected to one cycle of infection with PSIH1-H1-copGFP
(‘‘empty vector’’) or PSIH1-H1-copGFP-shAHR (‘‘AHR shRNA’’) using previ-
ously published methods (Trotta et al., 2012), then cultured for 14 days in
the presence of IL-15 plus DMSO carrier. After culture, phenotypic and func-
tional analyses of infected cells were performed via flow cytometry by gating
on GFP+ lymphocytes.
To confirm shRNA-mediated down-modulation of AHR expression, the NKL
cell line (a generous gift fromMichael Robertson, Indiana University, Indianap-
olis), which expressed AHR mRNA prior to infection, was infected in an iden-
tical manner with either PSIH1-H1-copGFP or PSIH1-H1-copGFP-shAHR. On
day 5 of culture, infected NKL cells expressing GFP were FACS sorted, and
AHR mRNA was measured via real-time RT-PCR as described above.
Statistical Analysis
For comparison of two conditions, data were analyzed using paired t tests.
Linear mixed models were used for analysis when using more than two treat-
ment conditions. Two-way ANOVAwas applied to test the interaction between
CD94 and CH-223191. All tests were two sided. p < 0.05 was considered sig-
nificant for single comparisons and after adjustment for multiple comparisons.
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